OBJECTIVE： To evaluate the pharmacoeconomic characteristics of dapagliflozin combined with metformin in the treatment of type 2 diabetes mellitus systematically. METHODS： Retrieved from Health Technology Assessment （HTA）， Cochrane Library， PubMed， Embase， CNKI， Wanfang and CBM during database establishment to Jul. 2017， published pharmacoeconomics literatures about dapagliflozin combined with metformin were collected， using “sodium-glucose-transporter-2 inhibitors” “SGLT2 inhibitor” “metformin” “dapagliflozin” “cost” “benefit” “utility” “effectiveness” “pharmacoeconomic” “economic” as English retrieval words and “SGLT2 inhibitor” “dage liejing” “metformin” “cost” “benefit” “utility” “effectiveness” as Chinese retrieval words. Outcome indexes included incremental cost， incremental effect， cost-effectiveness ratio and incremental cost-effectiveness ratio （ICER）. The results of the economic research in the included literatures were evaluated systematically. RESULTS： Totally of 4 literatures were included， and all of them were cost-effectiveness analysis. Dapagliflozin was  more cost-effective than sulfonylurea because the ICER of dapagliflozin were €2 709/QALY，€10 494/QALY，€7 939/QALY，€5 433/QALY，€4 767/QALY and €6 094/QALY in the UK， Greece， Denmark， Finland， Norway and Sweden， respectively， which were all lower than willingness-to-pay threshold. Dapagliflozin was more cost-effective than DPP-4 inhibitor， and the ICER were €7 200/QALY and €15 120/QALY in the UK and Greece， respectively， which were all lower than willingness-to-pay threshold. CONCLUSIONS： Current economic research shows compared with sulfonylurea and DDP-4 inhibitor， dapagliflozin is a cost-effective treatment alternative for patients with T2DM whose metformin regimen does not provide sufficient glycemic control.